Rocket Pharmaceuticals, Inc. (RCKT)
Stock Price:
$31.85 USD
0.89 (2.87%)
Updated December 1, 4:00 PM EST - Market closed
Key Info
| Market Cap |
1.76B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-98.64M |
| Shares Out |
55.23M |
| EPS (ttm) |
-1.82 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
December 1 |
| Last Price |
$31.85 |
| Previous Close |
$30.96 |
| Change ($) |
0.89 |
| Change (%) |
2.87% |
| Day's Open |
31.30 |
| Day's Range |
30.56 - 31.99 |
| Day's Volume |
299,766 |
| 52-Week Range |
9.71 - 34.68 |
More Stats
| Market Cap |
1.76B |
| Enterprise Value |
1.60B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
55.23M |
| Float |
n/a |
| EPS (basic) |
-1.82 |
| EPS (diluted) |
-1.82 |
| FCF / Share |
-1.90 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
9.14M |
| Short Ratio |
30.47 |
| Short % of Float |
n/a |
| Beta |
1.57 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
7.11 |
| Revenue |
n/a |
| Operating Income |
-94.72M |
| Net Income |
-98.64M |
| Free Cash Flow |
-104.66M |
| Net Cash |
161.91M |
| Net Cash / Share |
2.93 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-18.63% |
| ROE |
-41.64% |
| ROIC |
-43.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (12)
| Buy |
11 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$39.60*
(24.33% upside)
Low
34.0
Current: $31.85
High
47.0
Target: 39.60
*Average 12-month price target from 10 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | - | - | - | - | - | - | - | - |
| Operating Income | -76.15 | -71.16 | -19.77 | -7.57 | -20.40 | -7.70 | -6.65 | -5.85 |
| Net Income | -77.27 | -74.52 | -19.58 | -7.57 | -67.98 | -9.53 | -7.62 | -6.06 |
| Shares Outstanding | 49.01 | 39.38 | 6.80 | 6.83 | 4.58 | 0.26 | 0.25 | 0.25 |
| Earnings Per Share | -1.58 | -1.89 | -2.88 | -1.11 | -14.88 | -54.08 | -40.20 | -32.16 |
| Operating Cash Flow | -64.66 | -53.79 | -15.96 | -5.50 | -17.42 | -9.74 | -6.46 | -6.94 |
| Capital Expenditures | -23.27 | -1.43 | -0.76 | -0.34 | -0.41 | - | - | - |
| Free Cash Flow | -87.93 | -55.22 | -16.72 | -5.84 | -17.83 | -9.74 | -6.46 | -6.93 |
| Cash & Equivalents | 306 | 208 | 18.35 | 126 | 111 | 3.62 | 12.79 | 1.37 |
| Total Debt | 47.45 | 41.45 | - | 48.96 | - | 7.15 | 6.81 | 2.71 |
| Net Cash / Debt | 259 | 166 | 18.35 | 77.51 | 111 | -3.54 | 5.99 | -1.34 |
| Assets | 372 | 251 | 20.15 | 130 | 113 | 5.52 | 12.86 | 1.42 |
| Liabilities | 64.82 | 57.28 | 4.63 | 56.48 | 4.51 | 10.28 | 10.53 | 3.79 |
| Book Value | 307 | 194 | 15.52 | 73.17 | 109 | -51.56 | -38.90 | -30.93 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Rocket Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
84 |
| CEO |
Gaurav Shah |
Stock Information
| Ticker Symbol |
RCKT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: RCKT |
Description
Rocket Pharmaceuticals, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction, and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. It also has additional infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.